Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives
Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics, i.e., colistin, tobramycin, aztreonam lysine and levofloxacin, are used as maintenance treatment for CF patients...
Main Authors: | Giovanni Taccetti, Michela Francalanci, Giovanna Pizzamiglio, Barbara Messore, Vincenzo Carnovale, Giuseppe Cimino, Marco Cipolli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/10/3/338 |
Similar Items
-
Role of inhaled antibiotics in children and adolescents with cystic fibrosis: Experience from the tertiary care center
by: Danish Abdul Aziz, et al.
Published: (2022-01-01) -
The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics
by: Atqah AbdulWahab, et al.
Published: (2017-01-01) -
Current and Emerging Inhaled Antibiotics for Chronic Pulmonary <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> Infections in Cystic Fibrosis
by: Danni Li, et al.
Published: (2023-02-01) -
Use of inhaled tobramycin in patients with cystic fibrosis
by: A G Chermensky, et al.
Published: (2010-08-01) -
Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging
by: Carsten Schwarz, et al.
Published: (2021-12-01)